Second Tocilizumab Biosimilar Launches In US
Bio-Thera And Biogen’s Tofidence Version Follows Fresenius Kabi’s Tyenne From April
A second tocilizumab biosimilar has been launched in the US, with Bio-Thera and Biogen together introducing their Tofidence version just weeks after Fresenius Kabi launched its first-to-market Tyenne.
